èªå·±å ç«çŸæ£ã®å¶åŸ¡ã«é¢ããæ°ããªå 霢é¢é£Â T 现èãçºèŠ
ââèªå·±å ç«çŸæ£å¶åŸ¡ããå¥åº·é·å¯¿ç€ŸäŒã®å®çŸã«æåŸ ââ
çºè¡šã®ãã€ã³ã
1.匷åãªæäœç£çèªå°èœãšçŽ°èå·å®³æŽ»æ§ã䜵ãæã¡ãå 霢ãšèªå·±å ç«çŸæ£ã§å¢å ãã
ããThA(Age-associated helper T)现èããäžçã§åããŠåå®ããå现èãåçš®èªå·±å ç«
ãçŸæ£ã®ç æ 圢æã«ãããŠäžå¿çãªåœ¹å²ãæãããŠããããšãèŠåºããŸããã
2.æäœç£çèªå°èœãšçŽ°èå·å®³æŽ»æ§ã䜵ãæã€å 霢é¢é£Â T 现èã®å ±åã¯ä»ã«ãªããæ¬ç 究ã§
ãã¯ãThA 现èã®ç¹ç°ç现èè¡šé¢ããŒã«ãŒãšãã¹ã¿ãŒå¶åŸ¡éºäŒåã®åå®ããããã®çŸæ£å¶
ã埡ã¡ã«ããºã ãŸã§ããèšåºæ å ±ãå å³ããçŸæ£æšªæçãã«ããªããã¯ã¹è§£æãªã©ã®ææ³ã
ãçšããŠæããã«ããŸããã
3.èªå·±å ç«çŸæ£ã¯å ç«åŠçèåã圱é¿ããããšãç¥ãããŠãããã®ã®ããã®è©³çŽ°ãªã¡ã«ããº
ãã ã¯äžæãªãŸãŸã§ãããThA 现èã®ãããªã解æã¯ãèªå·±å ç«çŸæ£ã®ç æ 解æãæ°ããª
ãåµè¬æšçåå®ãåå¥åå»çã®å®çŸã«ç¹ããã®ã¿ãªãããå¥åº·é·å¯¿ãžã®éãåãéãããã
ããšãæåŸ ãããŸãã
æŠå¿µå³:å 霢ã«ããå¢å ãã ThA 现èãšæ°èŠæ²»çæ³éçºã®å¯èœæ§
æŠèŠ
ãæ±äº¬å€§åŠå»åŠéšéå±ç é¢ ã¢ã¬ã«ã®ãŒã»ãªãŠããå ç§ åŸè€ æ䜳 ç é¢èšºçå»ãé«æ© ç§äŸ å©æãåç° è¯ç¥ ç¹ä»»èšåºå»(ç 究åœæ)ãå倧åŠå€§åŠé¢å»åŠç³»ç ç©¶ç§ å ç«çŸæ£æ©èœã²ãã åŠè¬åº§ã®å€ªç° 峰人 ç¹ä»»å©æ(ç 究åœæ)ã岡æ åä¹ ç¹ä»»åææãå倧åŠé¢çäœé²åŸ¡è «çå ç§åŠè¬åº§ ã¢ã¬ã«ã®ãŒã»ãªãŠããåŠ è€å°Ÿ åå¿ ææãã«ããç 究ã°ã«ãŒãã¯ãçååŠç 究æ çåœå»ç§åŠç 究ã»ã³ã¿ãŒ äžé æ£å åŠæ¯ç¹å¥ç 究å¡ãç³å£ åæ ¶ ããŒã ãªãŒããŒãå±±æ¬ äžåœŠ ããŒã ãªãŒããŒããšã®å ±åç 究ã«ãããŠãèªå·±å ç«çŸæ£ã®ç æ å¶åŸ¡ã«é¢ããæ°ããªå 霢é¢é£Â T 现è(泚1)ãçºèŠããŸããã
ãèªå·±å ç«çŸæ£ã¯ãå ç«ãšããæ¬æ¥ã¯èº«äœãå®ãä»çµã¿ã«ç°åžžãèµ·ãããèªåã®çµç¹ãæ»æããŠããŸãç æ°ã§ãããã®çºçã«ã¯éºäŒçããã³ç°å¢çãªèŠå ãé¢äžããŸãããèªå·±å ç«çŸæ£ã®å€ããäžå¹Žä»¥éã«çºçã®ããŒã¯ãè¿ããããšããããå 霢ããéèŠãªèŠå ãšããŠç¥ãããŠããŸãããŸããå ç«åŠçãªçŽ°èã¬ãã«ã§ã®èåããèªå·±å ç«çŸæ£ã®çºçã«é¢ãã£ãŠãããšãèããããŠããŸãã
ãæ¬ç 究ã§ã¯ãå 霢ã§å¢å ãã T 现èãçºèŠãããThA(Age-associated helper T/å 霢é¢é£ãã«ããŒT)现èããšåä»ããŸãããThA 现èã¯ãè¥å¹Žéœ¢ã®èªå·±å ç«çŸæ£ã§ãå¢å ãããã®çŽ°èã¯å¥åº·ãªæ¹ã®Â ThA 现èãšã¯æ§è³ªãç°ãªãããšãåãããŸããã
ThA 现èã®æ©èœã詳现ã«èª¿ã¹ããšããããããŸã§ã¯å¥ã ã®çŽ°èãæ ããšèããããŠãããæäœç£çãå°ãæ©èœãšãåšå²ã®çŽ°èãå·å®³ããæ©èœã®Â 2 ã€ã䜵ãæã£ãŠããããšãåãããŸãããå 霢ã§å¢å ãããã€ããã 2 ã€ã®æ©èœãæã€çŽ°èã¯ãäžçã§åããŠã®çºèŠãšãªããŸãã
ã代衚çãªèªå·±å ç«çŸæ£ãšããŠãå šèº«æ§ãšãªããããŒãã¹(SLE)ãç¥ãããŠããŸããSLE ã¯ãèªåã«å¯Ÿããæäœã§ããæ§ã ãªèªå·±æäœãç£çãããå šèº«ã®èåšã®é害ãèªããçŸæ£ã§ãããé£ç ã«æå®ãããŠããŸããThA 现èã¯è¥å¹Žéœ¢ã®Â SLE çäŸã§ãå¢å ããŠãããå¥åº·ãªæ¹ãšæ¯ã¹Â B现è(泚 2)ã®æäœç£çãä¿é²ãããååãéåžžã«é«ãç£çããŠããããšãåãããŸããããŸããä»ã®Â T 现èãšæ¯èŒããŠãThA 现èã®éºäŒåçºçŸã®éãããSLE ã®ç æ°ã®å¢ããæã匷ãåæ ããŠããããšãåãããŸããã
æ¬ç 究ã§ã¯ãThA 现èã®Â 2 ã€ã®æ©èœã¯Â ZEB2 ãšããéºäŒåã§å¶åŸ¡ãããŠãããšããããšã®ç¹å®ã«ãæåããŸããã
ä»åã®ç 究ã§åŸãããç¥èŠã¯ãThA 现èããèªå·±å ç«å¿çãšå¥åº·é·å¯¿ã®éããç¥ãããšãã§ããéèŠãªçŽ°èã§ããããšã瀺åããŠãããèªå·±å ç«çŸæ£ã®æ°ããªæ²»çæ³éçºãå¥åº·é·å¯¿ç€ŸäŒå®çŸãžã®å±éãæåŸ ãããŸãã
å³Â 1:ThA 现èã«ããèªå·±å ç«çŸæ£å¶åŸ¡ã¡ã«ããºã ã®æŠå¿µå³
ThA 现èã¯ãB 现èããã®æäœç£çã®ä¿é²ãšã现èãå·å®³ãããšããæ©èœã䜵ãæã£ãŠãããThA 现èã¯Â T 现èå容äœãä»ããŠãèªå·±ã®æåã§ããèªå·±æåãªã©ãç¹ç°çã«èªèããŠæŽ»æ§åããããšãæ³å®ãããã现èå·å®³ã¯ãã°ã©ã³ã¶ã€ã (ã¿ã³ãã¯åè§£é µçŽ ã®äžçš®)ãªã©ãä»ããŠçºæ®ãããã掻æ§åãã ThA 现èã¯ãIL-21 ããã³Â CXCL13 ãåæ³ããŠÂ B 现èã®æäœç£çãä¿é²ããããã®äœçšã¯ãSLE ãªã©ã®ç æ°ãæªåãããããšãç¥ãããŠããã€ã³ã¿ãŒãã§ãã³Î±ãšãããµã€ãã«ã€ã³ã®æ¿åºŠãäœã®äžã§é«ãæã«ããã匷ããªããšèãããããèªå·±å ç«çŸæ£ã«ãããŠã¯ãThA 现èãä»ããäœçšã«ãããèåšãé害ãããäžæ¹ãå¥åº·ãªé«éœ¢è ã§ã¯ããã®äœçšãææçã®é²åŸ¡ãªã©ã«åããããããšãæ³å®ãããã
ä»åŸã¯ãèªå·±å ç«çŸæ£ããã³ãåè硬åãªã©ã®å 霢é¢é£çŸæ£ãå¥åº·é·å¯¿ã«ãããŠãThA 现èãã©ã®ããã«é¢ãã£ãŠãããã«ã€ãããã詳现ãªæ€èšãé²ããã
çºè¡šå 容
ãç 究ã°ã«ãŒãã¯ã代衚çãªÂ 10 ã®èªå·±å ç«çŸæ£ã®çäŸããã³å¥åžžäººãèš 416 äŸã®æ«æ¢¢è¡ãã28 çš®é¡ã®å ç«æ åœçŽ°èãååããéå»æ倧èŠæš¡ã®æ©èœã²ãã ããŒã¿ããŒã¹ãImmuNexUTã(Immunecell gene expression atlas from the University of Tokyo)ãæ§ç¯ãå ±åãããŸãã(Cell.184(11) 2021)ã
æ¬ããŒã¿ããŒã¹æ§ç¯æã®ãããŒãµã€ãã¡ããªãŒ(泚 3)ã®è©³çŽ°ãªèŠ³å¯ãããè¥å¹Žå¥åžžäººã§ã¯å°ãªããèªå·±å ç«çŸæ£ãé«éœ¢è ã§å¢å ãèªããéå»ã«ã¯å ±åã®ç¡ã现èéå£ãšããŠÂ ThA 现èãçºèŠãã7 幎éã«æž¡ãç 究ã®ææããŸãšããä»åçºè¡šããŸããã
å³Â 2:æ¬ç 究ã®å šäœå
æ¬ç 究ã§ã¯ãImmuNexUT ããŒã¿ããŒã¹ã§ååãã 8 çš®é¡ã®Â CD4 éœæ§Â T 现èã«ãThA 现èãå ãã 9 çš®é¡ã®çŽ°èãçšããŠãå¥åžžäººããã³Â 3 ã€ã®èªå·±å ç«çŸæ£çäŸã®æ€äœããããããŒãµã€ãã¡ããªãŒè§£æããã³Â RNA ã·ãŒã¯ãšã³ã¹(泚 4)ã«ããç¶²çŸ çãªéºäŒå解æãšãèšåºæ å ±ãšã®çµ±å解æãå®æœããã
ThA 现èã¯ãæ¢ç¥ã®ãã«ããŒCD4 éœæ§Â T 现èãšã¯éè€ã®ç¡ããšãã§ã¯ã¿ãŒã¡ã¢ãªãŒT 现èã®ãã¡ã现èè¡šé¢ã®Â CXCR3 ãšããååãäžçšåºŠã«çºçŸãã现èãšããŠåå®ãããŸãã(å³Â 3 å·Šå³)ãå 霢ã«ãããã®å²åã¯å¢å ããŸã(å³Â 3 å³å³)ã
å³Â 3:ãããŒãµã€ãã¡ããªãŒãçšãã ThA 现èã®åå®
ThA 现èã¯å·Šå³ã®ããã«ã现èè¡šé¢ã®Â CXCR3 ãšããã¿ã³ãã¯ãäžçšåºŠã«çºçŸãã现èãšããŠåå®ã§ããã
Â
ThA 现èã®ç¶²çŸ çãªéºäŒåçºçŸè§£æãè¡ã£ãçµæãThA 现èã¯ãæ¢ç¥ã®Â 8 çš®ã®Â CD4 éœæ§Â T 现èãšã¯ç°ãªãç¬èªã®éºäŒåçºçŸã®ç¹åŸŽãæããããšããŸãã现èå·å®³æ§ã®åŒ·ãååããšãŠãé«ãçºçŸããŠããããšãåãããŸããã
å³Â 4:现èå·å®³æ§Â T 现èãšããŠã®Â ThA 现è
å·Šå³:RNA ã·ãŒã¯ãšã³ã¹ããŒã¿äž»æååæ解æã®çµæãå·Šäžã®èµ€ãç¹Â 1 ã€ã 1 人ããåŸã
ãã ãã ThA 现èã®æ å ±ãè¡šããThA 现èã¯ä»ã®Â CD4 éœæ§Â T 现èãšã¯ç°ãªãéºäŒåçº
ãã çŸã®ç¹åŸŽãæã€ããšãåããã
äžå³:RNA ã·ãŒã¯ãšã³ã¹ã®çµæã®ãã¡ã现èå·å®³ã«é¢ããéºäŒåã®çºçŸéãã°ã©ãåããã
ãã ã®ãThA 现èã¯ä»ã®Â CD4 éœæ§Â T 现èãšæ¯ã¹ãŠãèãã现èå·å®³ã«é¢ããéºäŒåçºçŸ
ãã ãé«ãã
å³å³:é»åé¡åŸ®é¡èŠ³å¯äžã«ãããŠãThA 现èã¯ã代衚çãªçŽ°èå·å®³Â T 现èãšããŠç¥ããã
ãã CD8 éœæ§Â T 现èãšåæ§ã«ã现èå ã«çŽ°èå·å®³ã«é¢ããååãèããé¡ç²ã芳å¯ãã
ãã ã(èµ€ç¢å°)ã
ThA 现èã¯ãå€åœ©ãªèªå·±æäœç£çãç¹åŸŽãšããèªå·±å ç«çŸæ£ã§ãã SLE ã«ãããŠãå¢å ãèªããŸãããRNA ã·ãŒã¯ãšã³ã¹ã®ããŒã¿ãçšããŠå¥åžžäººãšéºäŒåçºçŸã®éãã確èªãããšãããå¥åžžäººããããB 现èã®æäœç£çèªå°ã«é¢ãã IL-21 ãšÂ CXCL13 ã®çºçŸãèããé«ãããšãåãããŸãããå®éã«ãè©Šéšç®¡å ã®å®éšã«ãããŠããThA 现èã¯åŒ·ãæäœç£çèªå°èœãèªããŸããã
å³Â 5:B 现èã®æäœç£çã匷ãèªå°ãã ThA 现è
å·Šå³:ThA 现èãšÂ B 现èãè©Šéšç®¡å ã§äžç·ã«å¹é€ããçµæ(é¢ç¯ãªãŠããçäŸ)ããããŸã§ã
ãã æã匷ãæäœç£çãå°ãããšãç¥ãããŠããæ¿Ÿèæ§Â CD4 éœæ§Â T(Tfh)现èãšåçšåºŠãŸ
ãã ã§ãThA 现èã¯Â B 现èã®æäœç£ç(IgG:ã€ã ãã°ãããªã³Â G)ãä¿é²ããã
äžå³:å·Šå³ãšåãå®éšç³»(é¢ç¯ãªãŠããçäŸ)ã«ãããŠãè©Šéšç®¡å ã§Â IL-21 ãããã¯Â CD84
ãã ãé»å®³ãããšãããB 现èã®æäœç£çãæå¶ãããã
å³å³:å·Šå³ãšåãå®éšç³»(å¥åžžäºº)ã«ãããŠãå¥åžžäººã§ã ThA 现èã CXCL13 ã¿ã³ãã¯ãç£
ãã çã(äžçªå³ã®ã°ã©ãã®ã°ã¬ãŒè¡šç€ºã®ããŒã¿)ããŸãã€ã³ã¿ãŒãã§ãã³Î±ãå ãããšæŽ
ãã ã«å¢åŒ·ããã(äžçªå³ã®ã°ã©ãã®é»è¡šç€ºã®ããŒã¿)ã
ThA 现èã«ãã B 现èã®æäœç£çãèªå°ããäœçšã¯ããããŸã§ãæã匷ãæäœç£çãå°ãããšãç¥ãããŠããæ¿Ÿèæ§Â CD4 éœæ§Â T(Tfh)现èãšåçšåºŠã§ãããTfh 现èã¯çŽ°èè¡šé¢ã«Â CXCR5ãšããã¿ã³ãã¯ãçºçŸããŠããŸãããThA 现èã¯ãããçºçŸãããç°ãªã现èãšãªããŸããTfh现èã¯ãªã³ãæ¿Ÿèã«ãããŠÂ B 现èã®æäœãç£çããããšãç¥ãããŠããŸãããè¿å¹Žããªã³ãæ¿Ÿèå€ã«ãããŠÂ B 现èã®æäœç£çãå°ã CD4 éœæ§Â T 现èãèªå·±å ç«çŸæ£ã«ãããŠç æ ãå¶åŸ¡ããããšã泚ç®ãããŠããŸãããã®æ§ãªÂ T 现èãšããŠã现èè¡šé¢ã«Â PD-1 ãšããååãçºçŸãã Tph(PD-1 éœæ§Â CXCR5 é°æ§Â CD4 éœæ§Â æ«æ¢¢ãã«ããŒÂ T)现èãæãè¯ãç¥ãããŠãã(Nature. 542,2017)ãäžççã«çããªç 究ããªãããŠããŸããTfh 现èã¯Â CXCR5 ãšããååãçºçŸãããªã³ãæ¿Ÿèå ã«éèµ°ããŸãããTph 现èã¯Â CXCR5 ãçºçŸããªãããããªã³ãæ¿Ÿèå ã«ç©æ¥µçã«å ¥ã蟌ãããšãã§ããŸãããäžæ¹ã§ãTph 现èã¯Â CXCL13 ãšããã¿ã³ãã¯ãçºçŸããããšã§ãB 现èãåŒãå¯ãããªã³ãæ¿Ÿèå€ã§ã B 现èã®æäœç£çãèªå°ã§ãããšèããããŠããŸãã
ããããªãããTph 现èã®ããŒã«ãŒã§ãã PD-1 ã¯ãT 现èã掻æ§åããã ãã§ãçºçŸããŠããŸãããšãããCXCR5 ãçºçŸããªã B 现èæäœç£çèªå°èœãæã€Â CD4 éœæ§Â T 现èã®ç¹ç°ç现èè¡šé¢ããŒã«ãŒã®åå®ã匷ãæãŸããŠããŸããã
CD4 éœæ§Â T 现èã¯ãç¹ç°çãªããŒã«ãŒãšãªã现èè¡šé¢ã¿ã³ãã¯ãšããã®çŽ°èã®æ©èœãå¶åŸ¡ãã転åå å(ãã¹ã¿ãŒå¶åŸ¡éºäŒå)ã®Â 2 ã€ãæãããšã§ãç¬ç«ãããµãã»ãããšèªããããŸãããããŸã§ãTh1ãTh2ãTh17ãå¶åŸ¡æ§Â T 现èãªã©ãããã®ãããªæ¹æ³ã§å®çŸ©ãããå€ãã®çŸæ£ã®ç æ 解æã«å¯äžããŠããŸããã
äžæ¹ã§ãTph 现èã¯ãPD-1 ãå¯äžã®ããŒã«ãŒã§ãããã®ã®ãäžè¿°ã®ããã«Â Tph 现èã ãã«çºçŸãããã®ã§ã¯ãªãããã¹ã¿ãŒå¶åŸ¡éºäŒåãåå®ãããŠããªãããšã課é¡ãšãªã£ãŠããŸãã
ä»åã®ç 究ã§åå®ãã ThA 现èã¯ãCXCR3 ãäžçšåºŠã®çºçŸãšããä»ã®Â CD4 éœæ§Â T 现èãµãã»ãããšéè€ããªãç¹ç°çãªããŒã«ãŒãæããŠããŸããããã§ãThA 现èãšÂ Tph 现èã«ã€ããŠãä»ã®Â CD4 éœæ§Â T 现èãµãã»ãããšã®éè€ã«ã€ã確èªããããšãããThA 现èã¯Â Tph 现èãé€ãä»ã®Â CD4 éœæ§ãµãã»ãããšã®éè€ã¯ç¡ã(å³Â 6 å·Šå³)ãäžæ¹ã§Â Tph 现èã¯å€ãã®æ¢ç¥ã®Â CD4 éœæ§Â T 现èãµãã»ãããšéè€ãèªããŸãã(å³Â 6 äžå³)ããŸããTph 现èã¯å 霢ã«ããå¢å ããããšã¯ãªã(å³Â 6 å³å³)ãThA 现èã«ããã Tph 现èãšã®éè€çã¯çŽÂ 10%ã®ã¿ã§ããããšãããThAã¯ç¬ç«ãã现èãµãã»ãããšèããããŸããã
å³Â 6:ThA 现èãšÂ Tph 现èã®ç°å
å·Šå³:ãããŒãµã€ãã¡ããªãŒãçšããŠãThA 现èãšä»ã®Â CD4 éœæ§Â T 现èãšã®éè€çãæ€èš
ãã ããçµæ(å¥åžžäººÂ 22äŸãSLE 11 äŸãé¢ç¯ãªãŠãã 16 äŸ)ãThA 现èã¯Â Tph 现èãš
ã®éè€ã¯çŽÂ 10%ã®ã¿ã§ãã£ãã
äžå³:å·Šå³ãšåãè©äŸ¡æ¹æ³ã«ãŠãTph 现èãšä»ã®Â CD4 éœæ§Â T 现èãšã®éè€çãæ€èšããçµ
æãTph 现èã¯ããããŸã§ã«ç¬ç«ãããµãã»ãããšããŠå®çŸ©ãããŠããæ§ã ãªÂ T 现è
ãµãã»ãããšéè€ãèªããã
å³å³:å·Šå³ãšåãããŒã¿ãçšããŠãTph 现èãšå¹Žéœ¢ã®çžé¢ãè©äŸ¡ããçµæãThA 现èãšç°ãª
ããTph 现èã¯å 霢ã«ããå¢å ã¯èªããªãã£ãã
Â
ããã«æ¬ç 究ã§ã¯ãThA 现èã ZEB2 ããã³Â TBX21 ãšãã 2 ã€ã®è»¢åå åã匷ãçºçŸããŠããããšãåå®ããThA ã®æ©èœçºçŸã«ãããŠã¯ç¹ã«Â ZEB2 éºäŒåããã¹ã¿ãŒå¶åŸ¡éºäŒåãšããŠæ©èœããããšãŸã§åå®ããŸããããŸããThA 现èã¯Â T 现èå容äœã®å€æ§æ§ããä»ã®Â T 现èãšæ¯ã¹èããäœãããšãããThA 现èãçäœå ã®æåç¹ç°çã«å¢æ®ããŠããããšã瀺åãããŸããã
æåŸã«ãSLE çäŸã®èšåºæ å ±ãšãThA 现èãå«ã 9 ã€ã®Â T 现èãµãã»ããã®Â RNA ã·ãŒã¯ãšã³ã¹ããŒã¿ãšã®çµ±å解æãè¡ããŸããããã®çµæãä»ã®Â T 现èã®éºäŒåå€åãšæ¯ã¹ãŠãSLE ã®çŸæ£æŽ»åæ§ã®åœ±é¿ãæã匷ãåããã®ã¯Â ThA 现èã§ããããšãåãããŸãã(å³Â 7 å·Šå³)ããŸããThA 现èã«ãããçºçŸå€åéºäŒåã®ã»ãšãã©ãçŸæ£æŽ»åæ§ã«é¢ãããšããç¥èŠãåŸãŸããããã®åŸåã¯ãä»ã®çŽ°èãµãã»ãããšæ¯èŒããŠãé¡èãªãã®ã§ãã(å³Â 7 å³å³)ã
å³Â 7:SLE ã«ããã RNA ã·ãŒã¯ãšã³ã¹ããŒã¿ãšèšåºæ å ±ã®çµ±å解æ
å·Šå³:RNA ã·ãŒã¯ãšã³ã¹ããŒã¿ããåŸãããäž»æååæãšåæ£æå解æã®çµæãçµã¿åã
ããèšåºæ å ±ã®åæ£ããå CD4 éœæ§Â T 现èãµãã»ããéºäŒåçºçŸå€åã«å¯ŸããŠäžã
ãè²¢ç®åºŠãæšå®ããçµæ( Variancepartitioning 解æ)ãå T 现èãµãã»ããã®éºäŒå
çºçŸå€åã«å¯ŸããŠãæ§å¥ã幎霢ãå ç«æå¶å€ããã¬ãããŸãã³äœ¿çšéãSLE ã®çŸæ£æŽ»
åæ§ããã©ã®çšåºŠèª¬æããããæ°åŠçã«âå åå¯äžâãšããŠç€ºããããã®çµæãThA
现èã«ãããŠçŸæ£æŽ»åæ§ã®å¯äžåºŠãæãé«ããšããçµæãåŸãããã
å³å³:çŸæ£ã®çºçã«é¢äžãããšèãããããçŸæ£ç¶æ ã·ã°ããã£ãŒéºäŒåã(éè²)ãšããŠã
å¥åžžäºº 察 é掻åæ§ SLEæ£è ã®çºçŸå€åéºäŒåãå®çŸ©ããçŸæ£ã®å¢æªã«é¢ããéºäŒå矀
ã§ãããçŸæ£æŽ»åæ§ã·ã°ããã£ãŒéºäŒåã(èµ€è²)ãšããŠãé掻åæ§Â SLE æ£è 察 é«çŸ
æ£æŽ»åæ§Â SLE æ£è ã®çºçŸå€åéºäŒåãå®çŸ©ããããã®çµæãThA现èã«ãããçºçŸå€
åéºäŒåã®ã»ãšãã©ããçŸæ£æŽ»åæ§ã·ã°ããã£ãŒéºäŒåã(èµ€è²)ã«ããå ããããŠã
ããä»ã®Â T 现èãšã¯å€§ããªéããèªããã
ä»åŸã®å±æ
ãä»åã®ç 究ã§ã¯ãæäœç£çä¿é²èœãšçŽ°èå·å®³æŽ»æ§ã䜵ãæã¡ãå 霢ãšèªå·±å ç«çŸæ£ã§å¢å ããæ°ãã ThA 现èãåå®ããŸãããThA 现èã®éºäŒåå€åã¯ãSLE ã®çŸæ£æŽ»åæ§ãéåžžã«åŒ·ãåæ ããŠãããThA 现èãèªå·±å ç«çŸæ£ã®æ°ããªæ²»çã¿ãŒã²ããã«ãªãå¯èœæ§ã瀺åãããŸããã
现èãå·å®³ãã T 现èã«ã€ããŠã¯ãæ§ã ãªèªå·±å ç«çŸæ£ã§å¢å ããããšãç¥ãããŠããäžæ¹ã110 æ³ãè¶ ããè¶ é«éœ¢è ã«ãããŠãèããå¢å ããŠããããšãå ±åãããŠããŸãã
ã€ãŸããèªå·±å ç«çŸæ£çºçãšãé«éœ¢è ã«ãããå ç«æ©èœã®ç¶æã®äž¡æ¹ã«ã现èå·å®³æ§Â T 现èãé¢ä¿ããŠãããšèããããŸããThA 现èã®çŽ°èãå·å®³ããæ©èœããã©ã®ããã«é¢ãã£ãŠãããã®è§£æã¯ä»åŸã®èª²é¡ã§ãã
å 霢ã§å¢å ãã ThA 现èãèªå·±å ç«çŸæ£ã«ãããŠäžå¿ç圹å²ãæãããŠããããšãããThA现èã®æŽãªãç 究ã¯ãèªå·±å ç«å¿çãšå¥åº·é·å¯¿ã®éããç¥ãããšãã§ããå¯èœæ§ãå å ããŠãããä»åŸã®æ²»çå¿çšãžã®å±éãæåŸ ãããŸãã
çšèªè§£èª¬
(泚1) T 现è
T 现èã¯ãªã³ãçã®äžçš®ã§ããã«ããŒT 现è(Th 现è)ãå¶åŸ¡æ§Â T 现èã现èå·å®³æ§Â T 现èãªã©ãã®æ©èœã«ããåé¡ããªãããŠããŸããCD4 éœæ§Â T 现èã¯ãTh1 现èãTh2 现èãTh17 现èãTfh 现èãªã©ã®ãã«ããŒT 现èãæå¶èœãæã£ãå¶åŸ¡æ§Â T 现èãªã©ã«åé¡ãããŸããCD8 éœæ§Â T现èã¯ããã©ãŒT 现èãšããŠç¥ããã现èå·å®³èœãæããããšããã®ç¹åŸŽã§ããThA 现èã¯Â CD4éœæ§ã®ãã«ããŒT 现èãšããŠÂ B 现èã®æäœç£çãèªå°ãããšããæ©èœã ãã§ãªããCD4 éœæ§Â T 现èã§ãããªãããã©ãŒT 现èãšããŠã®çŽ°èå·å®³èœã䜵ãæã€ãšããç¹åŸŽãæããŠããŸãã
(泚2) B 现è
B 现èã¯ãªã³ãçã®äžçš®ã§ãæäœãç£çããŸããæäœã¯ç¹å®ã®æåã«çµåããç åæ§ã®ããç°ç©ãªã©ãçäœå ããé€å»ããäœçšãæããŠããŸããCD4 éœæ§ãã«ããŒT 现èã®Â 1 ã€ã§ãã Tfh 现èã¯äž»ã«ãªã³ãæ¿Ÿèå ã«ããããThA 现èã¯äž»ã«ãªã³ãæ¿Ÿèå€ã«ããã B 现èã®æäœç£çãèªå°ãããšèããããŸããèªå·±å ç«çŸæ£ã§ã¯ããã°ãã°èªå·±ã®æåãèªèããèªå·±æäœãæ€åºããããã®ç æ 圢æã«é¢äžãããã®ãçŸæ£æŽ»åæ§ãåæ ãããã®ã蚺æã«æçšãªãã®ãªã©ãç¥ãããŠããŸãã
(泚3) ãããŒãµã€ãã¡ããªãŒ
éåžžã现èæžæ¿ããã液äœãè€æ°ã®èå æšèãããæäœã§æšèåŸã现èãäžåã«æµããŠããç¶æ ã«ããã¬ãŒã¶ãŒå ãç §å°ããŠåŸãããå ã®åŒ·ããé»æ°ä¿¡å·ã«çœ®æããŠå®éåããããšã§ã现èäžã€äžã€ã®è©³çŽ°ãªæ å ±ãåŸãããšãã§ããæ©æ¢°ã§ããç®çãšãã现èãååããæ©èœãæããæ©çš®ããããŸãã
(泚4) RNA ã·ãŒã¯ãšã³ã¹
次äžä»£ã·ãŒã±ã³ãµãŒãšããæ©æ¢°ãçšããŠã¡ãã»ã³ãžã£ãŒRNA(mRNA)ãªã©ã®é åæ å ±ãèªã¿åã解æææ³ã§ããããã§åŸãããé åæ å ±ãã RNA ã®çºçŸéãæ°å€åããããšã§ãéºäŒåçºçŸãªã©ãç¶²çŸ çã«èª¿ã¹ã解æææ³ã§ãã